What is the share price of Aarti Drugs Ltd (AARTIDRUGS) today?
The share price of AARTIDRUGS as on 29th May 2026 is ₹380.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Aarti Drugs Ltd (AARTIDRUGS) share?
The past returns of Aarti Drugs Ltd (AARTIDRUGS) share are- Past 1 week: 0.28%
- Past 1 month: -0.73%
- Past 3 months: 3.65%
- Past 6 months: -8.67%
- Past 1 year: -19.59%
- Past 3 years: -14.30%
- Past 5 years: -47.70%
What are the peers or stocks similar to Aarti Drugs Ltd (AARTIDRUGS)?
The peers or stocks similar to Aarti Drugs Ltd (AARTIDRUGS) include:What is the market cap of Aarti Drugs Ltd (AARTIDRUGS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aarti Drugs Ltd (AARTIDRUGS) is ₹3471.91 Cr as of 29th May 2026.What is the 52 week high and low of Aarti Drugs Ltd (AARTIDRUGS) share?
The 52-week high of Aarti Drugs Ltd (AARTIDRUGS) is ₹564.05 and the 52-week low is ₹318.95.What is the PE and PB ratio of Aarti Drugs Ltd (AARTIDRUGS) stock?
The P/E (price-to-earnings) ratio of Aarti Drugs Ltd (AARTIDRUGS) is 17.81. The P/B (price-to-book) ratio is 2.54.Which sector does Aarti Drugs Ltd (AARTIDRUGS) belong to?
Aarti Drugs Ltd (AARTIDRUGS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Aarti Drugs Ltd (AARTIDRUGS) shares?
You can directly buy Aarti Drugs Ltd (AARTIDRUGS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Aarti Drugs Ltd
AARTIDRUGS Share Price
NSE₹380.402.69% (-10.50)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
AARTIDRUGS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
AARTIDRUGS Performance & Key Metrics
AARTIDRUGS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 17.81 | 2.54 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.84 | 6.22 | 0.48% |
100%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
AARTIDRUGS Company Profile
Aarti Drugs Limited is a pharmaceutical company offering active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antifungals, antibiotic, antidiabetic, sedative and vitamins.
SUNPHARMA
PE Ratio
37.61
37.61
1Y Return
5.85%
5.85%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
69.82
69.82
1Y Return
39.53%
39.53%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
29.17
29.17
1Y Return
5.14%
5.14%
Buy Reco %
62.86
62.86
DRREDDY
PE Ratio
25.87
25.87
1Y Return
4.43%
4.43%
Buy Reco %
51.52
51.52
ZYDUSLIFE
PE Ratio
21.52
21.52
1Y Return
16.54%
16.54%
Buy Reco %
53.57
53.57
AARTIDRUGS Sentiment Analysis
AARTIDRUGS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
AARTIDRUGS Stock Summary · February 2026
In Q3 FY26, the company faced operational challenges, including low utilization rates and shipment delays, yet managed to achieve a 7% year-on-year volume growth in its standalone business, driven by strong export performance in formulations. Despite a 10% decline in EBITDA, a significant 58% increase in profit after tax reflects robust bottom-line resilience. Management remains optimistic, projecting a gross margin target of 36% for FY27, supported by strategic investments in oncology and improved operational stability. The company is also exploring new technologies and expanding production capacity, particularly in metformin and downstream products, to enhance revenue streams and address competitive pressures from aggressive pricing in the market.
AARTIDRUGS Stock Growth Drivers
AARTIDRUGS Stock Growth Drivers
7Operational Growth and Capacity Utilization
Aarti Drugs Limited has achieved a 7% year-on-year volume growth in its standalone business segment,
Positive Financial Performance
In Q3 FY '26, Aarti Drugs Limited reported consolidated revenue of INR 602.9 crores, an
AARTIDRUGS Stock Challenges
AARTIDRUGS Stock Challenges
5Production Challenges and Capacity Utilization
The company has faced significant production challenges, including low utilization levels due to weaker antibiotic
Financial Performance Decline
The standalone business has experienced a decline in performance, with gross margins affected by inventory
AARTIDRUGS Forecast
AARTIDRUGS Forecasts
Price
Revenue
Earnings
AARTIDRUGS Share Price Forecast
AARTIDRUGS Share Price Forecast
2026
Current
₹380.40
Baseline
Forecast for May 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹380.40
Baseline
Forecast for May 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
AARTIDRUGS Company Revenue Forecast
AARTIDRUGS Company Revenue Forecast
2026
Current
₹2.57
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹2.57
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
AARTIDRUGS Stock EPS (Earnings Per Share) Forecast
AARTIDRUGS Stock EPS (Earnings Per Share) Forecast
2026
Current
₹21.36
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹21.36
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
AARTIDRUGS
AARTIDRUGS
Income
Balance Sheet
Cash Flow
Quarterly Normal View
AARTIDRUGS Income Statement
AARTIDRUGS Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 607.61 | 621.07 | 556.45 | 599.81 | 568.50 | 678.63 | 590.82 | 652.88 | 602.94 | 721.06 | ||||||||||
Operating & Other expenses | 535.80 | 534.18 | 490.38 | 531.28 | 494.87 | 583.43 | 516.43 | 568.51 | 546.68 | 624.50 | ||||||||||
EBITDA | 71.81 | 86.89 | 66.07 | 68.53 | 73.63 | 95.20 | 74.39 | 84.37 | 56.26 | 96.56 | ||||||||||
| Depreciation/Amortization | 12.66 | 13.58 | 13.38 | 13.72 | 13.80 | 14.88 | 14.72 | 16.26 | 17.95 | 18.04 | ||||||||||
| PBIT | 59.15 | 73.31 | 52.69 | 54.81 | 59.83 | 80.32 | 59.67 | 68.11 | 38.31 | 78.52 | ||||||||||
| Interest & Other Items | 7.60 | 9.13 | 8.71 | 8.93 | 9.07 | 9.16 | 8.56 | 7.70 | 9.29 | 8.16 | ||||||||||
| PBT | 51.55 | 64.18 | 43.98 | 45.88 | 50.76 | 71.16 | 51.11 | 60.41 | 29.02 | 70.36 | ||||||||||
| Taxes & Other Items | 14.88 | 16.81 | 10.74 | 10.87 | 13.71 | 8.30 | -2.80 | 15.13 | -11.52 | 15.17 | ||||||||||
| Net Income | 36.67 | 47.37 | 33.24 | 35.01 | 37.05 | 62.86 | 53.91 | 45.28 | 40.54 | 55.19 | ||||||||||
| EPS | 3.99 | 5.15 | 3.62 | 3.83 | 4.06 | 6.88 | 5.91 | 4.95 | 4.44 | 6.05 |
AARTIDRUGS Company Updates
FY 2026FY 2026
Investor Presentation
May 16PDF
Feb 3PDF
Nov 7PDF
Jul 19PDF
AARTIDRUGS Stock Peers
AARTIDRUGS Past Performance & Peer Comparison
AARTIDRUGS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Aarti Drugs Ltd | 17.81 | 2.54 | — |
| Sun Pharmaceutical Industries Ltd | 37.61 | 5.96 | 0.89% |
| Torrent Pharmaceuticals Ltd | 69.82 | 19.67 | — |
| Cipla Ltd | 29.17 | 3.62 | 0.93% |
AARTIDRUGS Stock Price Comparison
Compare AARTIDRUGS with any stock or ETFCompare AARTIDRUGS with any stock or ETF
AARTIDRUGS
AARTIDRUGS Holdings
AARTIDRUGS Shareholdings
AARTIDRUGS Promoter Holdings Trend
AARTIDRUGS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
AARTIDRUGS Institutional Holdings Trend
AARTIDRUGS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
AARTIDRUGS Shareholding Pattern
AARTIDRUGS Shareholding Pattern
AARTIDRUGS Shareholding History
AARTIDRUGS Shareholding History
Foreign Institutions
Mutual Funds Invested in AARTIDRUGS
Mutual Funds Invested in AARTIDRUGS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Aarti Drugs Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 6.7373% | Percentage of the fund’s portfolio invested in the stock 1.34% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/86 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.9355% | Percentage of the fund’s portfolio invested in the stock 1.04% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 31/44 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8988% | Percentage of the fund’s portfolio invested in the stock 1.02% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 24/33 (0) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing AARTIDRUGS stock
smallcases containing AARTIDRUGS stock
Looks like this stock is not in any smallcase yet.
AARTIDRUGS Events
AARTIDRUGS Events
AARTIDRUGS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
AARTIDRUGS Dividend Trend
No dividend trend available
AARTIDRUGS Upcoming Dividends
AARTIDRUGS Upcoming Dividends
No upcoming dividends are available
AARTIDRUGS Past Dividends
AARTIDRUGS Past Dividends
Cash Dividend
Ex DateEx DateFeb 9, 2026
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Feb 9, 2026
Cash Dividend
Ex DateEx DateFeb 4, 2025
Interim
Interim | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Feb 4, 2025
Cash Dividend
Ex DateEx DateFeb 6, 2024
Interim
Interim | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Feb 6, 2024
Cash Dividend
Ex DateEx DateFeb 8, 2023
Interim
Interim | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Feb 8, 2023
Cash Dividend
Ex DateEx DateFeb 9, 2022
Interim
Interim | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Feb 9, 2022
AARTIDRUGS Stock News & Opinions
AARTIDRUGS Stock News & Opinions
Articles & Videos
Earnings
Earnings
Aarti Drugs consolidated net profit declines 12.20% in the March 2026 quarterNet profit of Aarti Drugs declined 12.20% to Rs 55.19 crore in the quarter ended March 2026 as against Rs 62.86 crore during the previous quarter ended March 2025. Sales rose 6.43% to Rs 720.30 crore in the quarter ended March 2026 as against Rs 676.76 crore during the previous quarter ended March 2025. For the full year,net profit rose 15.91% to Rs 194.92 crore in the year ended March 2026 as against Rs 168.16 crore during the previous year ended March 2025. Sales rose 7.47% to Rs 2565.31 crore in the year ended March 2026 as against Rs 2387.03 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales720.30676.76 6 2565.312387.03 7 OPM %13.3013.79 -12.0512.03 - PBDT88.4086.04 3 277.87267.55 4 PBT70.3671.16 -1 210.90211.77 0 NP55.1962.86 -12 194.92168.16 16 Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
Earnings
Aarti Drugs standalone net profit declines 26.87% in the March 2026 quarterNet profit of Aarti Drugs declined 26.87% to Rs 44.96 crore in the quarter ended March 2026 as against Rs 61.48 crore during the previous quarter ended March 2025. Sales rose 1.40% to Rs 631.68 crore in the quarter ended March 2026 as against Rs 622.96 crore during the previous quarter ended March 2025. For the full year,net profit rose 7.57% to Rs 169.22 crore in the year ended March 2026 as against Rs 157.31 crore during the previous year ended March 2025. Sales rose 3.99% to Rs 2260.39 crore in the year ended March 2026 as against Rs 2173.65 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales631.68622.96 1 2260.392173.65 4 OPM %12.5514.23 -11.5412.08 - PBDT73.5282.88 -11 236.95246.54 -4 PBT58.5770.67 -17 181.31198.75 -9 NP44.9661.48 -27 169.22157.31 8 Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Corporate
Aarti Drugs to announce Quarterly ResultAarti Drugs will hold a meeting of the Board of Directors of the Company on 15 May 2026.
2 weeks agoCapital Market - Live
Spotlight
Spotlight
Aarti Drugs gains as arm incorporates step-down subsidiary in ChileWith this incorporation, Tripharma Chile SpA becomes a step-down subsidiary of Aarti Drugs. The newly formed entity has been established to market formulation drugs and participate in government tenders as well as the private pharmaceutical market in Chile. The business activities of the new subsidiary are aligned with those of its holding companies. The cost of subscription stands at 1,000,000 Chilean pesos towards share capital contribution, comprising 1,000,000 shares. The entire share capital of Tripharma Chile SpA will be held by Pinnacle Chile SpA, making it a wholly owned step-down subsidiary of the company. Aarti Drugs was established in the year 1984 and forms part of the $6 billion Aarti Group of Industries. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates and speciality chemicals and produces formulations with its wholly-owned subsidiary, Pinnacle Life Science. The company reported a 9.4% increase in consolidated net profit to Rs 40.54 crore on an 8.1% rise in net sales to Rs 601.71 crore in Q3 FY26 as compared with Q3 FY25. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Board of Aarti Drugs recommends interim dividendAarti Drugs announced that the Board of Directors of the Company at its meeting held on 3 February 2026, inter alia, have recommended the interim dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Earnings
Aarti Drugs consolidated net profit rises 9.42% in the December 2025 quarterNet profit of Aarti Drugs rose 9.42% to Rs 40.54 crore in the quarter ended December 2025 as against Rs 37.05 crore during the previous quarter ended December 2024. Sales rose 8.10% to Rs 601.71 crore in the quarter ended December 2025 as against Rs 556.60 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales601.71556.60 8 OPM %9.1511.09 - PBDT46.9764.56 -27 PBT29.0250.76 -43 NP40.5437.05 9 Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Earnings
Aarti Drugs standalone net profit declines 12.17% in the December 2025 quarterNet profit of Aarti Drugs declined 12.17% to Rs 33.84 crore in the quarter ended December 2025 as against Rs 38.53 crore during the previous quarter ended December 2024. Sales rose 2.77% to Rs 528.80 crore in the quarter ended December 2025 as against Rs 514.54 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales528.80514.54 3 OPM %8.0011.71 - PBDT36.5864.05 -43 PBT21.7152.03 -58 NP33.8438.53 -12 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Aarti Drugs fixes record date for interim dividendAarti Drugs has fixed 09 February 2026 as record date for the purpose of payment of interim dividend. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Aarti Drugs to discuss resultsAarti Drugs will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Earnings
Aarti Drugs consolidated net profit rises 29.33% in the September 2025 quarterNet profit of Aarti Drugs rose 29.33% to Rs 45.28 crore in the quarter ended September 2025 as against Rs 35.01 crore during the previous quarter ended September 2024. Sales rose 9.10% to Rs 652.79 crore in the quarter ended September 2025 as against Rs 598.33 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales652.79598.33 9 OPM %12.9111.21 - PBDT76.6759.60 29 PBT60.4145.88 32 NP45.2835.01 29 Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.81%, vs industry avg of 9.86%
Over the last 5 years, market share decreased from 0.71% to 0.57%
Over the last 5 years, net income has grown at a yearly rate of 3.52%, vs industry avg of 19.71%